Association between the SLC6A3 A1343G polymorphism and schizophrenia

Quirino Cordeiro¹, Jacqueline Siqueira-Roberto², Homero Vallada³

ABSTRACT
Epidemiological studies have demonstrated that the genetic component is an important risk factor for the development of schizophrenia. The genes that codify the different compounds of the dopaminergic system have created interest for molecular investigations in patients with schizophrenia because the antipsychotic drugs, especially those of first generation, act on this cerebral system. Thus the aim of the present study was to investigate the possible association between a new single nucleotide polymorphism (rs6347) located in exon 9 of the protein transporter (SLC6A3) and schizophrenia. The distribution of the alleles and genotypes of the studied polymorphism was investigated in a sample of 235 patients and 834 controls matched by gender and age. There were statistical differences in the allelic ($\chi^2=5.97$, 1 d.f., $p=0.01$, OR=1.33–1.05<OR<1.69) and genotypic ($\chi^2=6.56$, 2 d.f., $p=0.03$) distributions between patients and controls. Thus the SLC6A3 A1343G polymorphism was associated to the SCZ phenotype in the investigated sample.

Key words: association study, dopamine, dopamine transporter, genetics, psychosis.

Associação entre o polimorfismo A1343G do SLC6A3 e esquizofrenia

RESUMO
Estudos epidemiológicos têm demonstrado que o componente genético é um importante fator de risco para a esquizofrenia. Os genes que codificam os diferentes componentes do sistema dopaminérgico passaram a despertar interesse para estudos moleculares em pacientes com esquizofrenia, pois os antipsicóticos, em especial os de primeira geração, exercem sua ação nesse sistema. Assim, o objetivo do presente estudo foi investigar a associação entre um novo polimorfismo de nucleotídeo único (rs6347) localizado no exon 9 do gene do transportador de dopamina (SLC6A3) e esquizofrenia. Um total de 235 pacientes e 834 controles pareados para sexo e idade foi selecionado para a investigação da distribuição dos alelos e gênitos do polimorfismo investigado entre os grupos de pacientes e controles. Houve diferenças estatisticamente significantes nas distribuições alélicas ($\chi^2=5.97$, 1 d.f., $p=0.01$, OR=1.33–1.05<OR<1.69) e genotípicas ($\chi^2=6.56$, 2 d.f., $p=0.03$) entre pacientes e controles. Assim, o polimorfismo SLC6A3 A1343G mostrou associação com esquizofrenia na amostra estudada.

Palavras-chave: estudo de associação, dopamina, transportador de dopamina, genética, psicose.

Schizophrenia (SCZ) is a psychiatric disorder characterized by psychotic symptoms, alterations of thought, affect, volition and behavior and affects some 1% of the general population. Genetic epidemiological investigations have suggested that there is an important participation of a genetic component on the etiology of SCZ and heritability estimates as high as 80% have been reported¹. The mode of inheritance is complex showing a polygenic-environmental interaction. The role of a sin-

¹MD, PhD. Researcher of the Genetics and Pharmacogenetics Program (PROGENE), Department of Psychiatry, University of São Paulo Medical School (FMUSP), São Paulo SP, Brazil; ²BSc. Researcher of the PROGENE. Department of Psychiatry, FMUSP; ³MD, PhD. Coordinator of the PROGENE, Associate Professor, Department of Psychiatry, FMUSP.
Some of the most investigated genes in studies of vulnerability to SCZ are those that code for proteins of the dopaminergic system because of the evidences of the role of central dopamine pathways in the pathophysiology of the disorder. Stimulant drugs, that block reuptake of dopamine or facilitate its release on neuronal synapses, may induce psychotic symptoms. L-DOPA has also been related to psychotic symptoms through variable release of dopamine into the synapses. Some antipsychotic drugs correlate their efficacy with their action at dopaminergic receptors. Therefore, genes involved in the dopaminergic system are potential targets for genetic association investigations with SCZ.

Polymorphisms in dopamine receptors genes have been widely investigated as risk factors for SCZ development, however the results have been inconclusive. Another possible candidate for such investigations is the dopamine transporter gene (SLC6A3 or DAT1). The dopamine transporter plays an important role in the regulation of dopamine levels and neurotransmission by mediating the active re-uptake of synaptic dopamine back into the neurons. Two post-mortem studies on SLC6A3 binding and SCZ showed decreased striatal SLC6A3 density in chronic SCZ. A recent study using positron emission tomography found lower SLC6A3 density in sites in the basal ganglia, particularly in the middle third of putamen, in chronic SCZ patients than controls. This may suggest a decreased expression of SLC6A3 in a subset of chronic SCZ patients.

The SLC6A3 was cloned and mapped to human chromosome 5 (5p15.3). A new single nucleotide polymorphism (SNP) was identified in exon 9 of the SLC6A3 (rs6347). There is an A1343G substitution, however this is a synonymous polymorphism and there is no amino-acide change (Ser/Ser). As far as we know the present study is the first one investigating the SLC6A3 A1343G polymorphism as a risk factor for SCZ development.

**METHOD**

**Sample**

Our sample was consisted of 235 (male=152: 64.68%; female=83: 35.32%) Brazilian SCZ patients, and recruited at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo Medical School. The diagnosis of SCZ was made according to the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria, based on a clinical interview conducted by a psychiatrist. A total of 834 (male=520: 62.35%; female=314: 37.65%) healthy control subjects were selected from unrelated subjects admitted to the Blood Donation Center of the Fundação Pró-Sangue of the University of São Paulo Medical School.

All patients and control subjects provided written informed consent for taking blood samples. Ethical approval for the study was obtained from the Ethics Committee at the Hospital das Clínicas, University of São Paulo Medical School (CAPPesq).

**DNA extraction**

Blood samples (10 mL) were collected from all participants of the study, and DNA was extracted from leukocytes using the “salting out” protocol.

**Genotyping**

Genotyping of the investigated polymorphism for this study was performed blind to the clinical status of the individuals according to Greenwood et al. and Guindali et al.

To avoid errors, genotyping was read by two independently trained research technicians. When a disagreement arose the genotyping was repeated. In addiction, random re-genotyping was repeated in 20% of the sample.

**Statistical analysis**

The statistical power of the sample was evaluated using the CaTS Program (Center for Statistical Genetics – The University of Michigan) (http://www.sph.umich.edu/csg/abecasis/CaTS/index.html).

A test for deviations from the Hardy-Weinberg equilibrium was performed using the HWE program.

Allelic and genotypic distributions of the SLC6A3 A1343G polymorphism were compared between 235 patients and 834 controls. Chi-square test, used to investigate possible association between genotypes and alleles with SCZ, was performed by the EpInfo version 6.0. Chi-square test was also used to investigate difference between gender distribution between the groups of patients and controls. Differences of age between the investigated groups were analyzed using student’s t-test.

For all statistic tests the level of significance adopted was α<0.05 or 5%.

**RESULTS**

The power of the sample, based on 235 patients and 834 controls, disorder prevalence of 1%, average allelic frequency around 20%, multiplicative model with the genotype relative risk=1.5 and significance level of 0.05, was 97%.

There were no significant deviations from Hardy-Weinberg equilibrium in the patients (p=0.28) and controls (p=0.69) samples for the SLC6A3 A1343G polymorphism.
Schizophrenia and polymorphism SLC6A3 A1343G
Cordeiro et al.

For patients, mean age was 28.3±6.9 years (19-64) and median age was 26.4 years. For controls, mean age was 31.2±8.3 years (18-79) and median age was 29.1 years. There was no statistical difference related to age between the groups of patients and controls (p=0.21). Statistical analysis did not evidence difference related to gender distribution between the groups investigated as well (c²=0.43; p=0.51).

There were statistical differences in the allelic (c²=5.97, 1d.f., p=0.01, OR=1.33–1.05<OR<1.69) and genotypic (c²=6.56, 2d.f., p=0.03) distributions between patients and controls (Table).

**DISCUSSION**

Findings of post-mortem and neuroimaging studies have suggested that SLC6A3 may play a role in the pathophysiology of SCZ. The evidences of involvement of the dopaminergic system in the pathophysiology of SCZ have collaborated to the investigation of genetic polymorphisms of this cerebral pathway on such disorder. There are previous studies that investigated the role of different SLC6A3 polymorphisms as risk factors for SCZ development however to our knowledge this is the first investigation to perform an association study between the SLC6A3 A1343G polymorphism and such disorder. This is a synonymous polymorphism and it does not promote a change of amino acids (Ser/Ser). However the investigation of synonymous polymorphisms is important because they may in linkage disequilibrium with another polymorphism on SLC6A3 which is a gene of interest for SCZ research. Moreover recent study has demonstrated that synonymous polymorphisms may alter gene translation. Duan et al. found that some synonymous mutations in the human DRD2 gene have functional effects, alter the predicted mRNA folding, led to a decrease in mRNA stability and translation, and dramatically change dopamine-induced up-regulation of DRD2 expression, indicating that synonymous variations can have effects on pathophysiological aspects of psychiatric disorders such as SCZ.

As the investigated polymorphism may be in linkage disequilibrium with another polymorphism on SLC6A3 which could influence the risk for the SCZ, it could be premature to assess the validity of the association found in the present work. Moreover in populations of highly admixed ethnicity like the Brazilian one, we may face problems about ethnical stratification. Physical phenotype in Brazil is not an adequate predictor of genomic ancestry what difficult the ethnical matching in case-control studies. However the fact that the present sample (patients and controls) is in Hardy-Weinberg equilibrium indicates that our sample may not have important problems regarding population stratification. It is also important to note that ethical matching conducted using genetic markers was performed in part of our sample in a case-control study with cocaine dependence and the results showed that, despite the ethnic admixture in Brazil, the ethnic stratification was not a bias in that case.

In conclusion, the results of the present investigation provide evidence for the association between the polymorphism SLC6A3 A1343G polymorphism and SCZ in our Brazilian sample. However to confirm the association of this polymorphism with SCZ further studies must be conducted focusing on ethnical aspects. It is always important to consider the possibility that the investigated polymorphism is in linkage disequilibrium with non-identified genes that are in fact those contributing to the pathogenesis of SCZ or even with other polymorphisms within the SLC6A3 therefore more comprehensive polymorphisms coverage within the SLC6A3 is warranted.

<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>Cases (%)</th>
<th>Controls (%)</th>
<th>χ²</th>
<th>d.f.</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotypes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A/A</td>
<td>132 (56.17)</td>
<td>393 (47.12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A/G</td>
<td>84 (35.74 )</td>
<td>356 (42.69)</td>
<td>6.56</td>
<td>2</td>
<td>0.03</td>
</tr>
<tr>
<td>G/G</td>
<td>19 (8.09)</td>
<td>85 (10.19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>235 (100)</td>
<td>834 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alleles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>348 (74.04)</td>
<td>1142 (68.47)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>122 (25.96)</td>
<td>526 (31.53)</td>
<td>5.97</td>
<td>1</td>
<td>0.01</td>
</tr>
<tr>
<td>Total</td>
<td>470 (100)</td>
<td>1668 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

χ²: Chi-square test; DF: degrees of freedom; P: probability.
considered an important gene given its potential important influence on the risk for SCZ development.

REFERENCES
